Zymeworks Closes Acquisition of Kairos Therapeutics.
23 March 2016 - Canadian biotherapeutics company Zymeworks Inc. has completed the acquisition of Kairos Therapeutics, a specialist in antibody drug conjugates that was spun out of The Centre for Drug Research and Development, the company said.
Zymeworks said that the integration of Kairos' technology and pipeline with its research platforms creates one of the industry's leading biologics drug discovery and development organisations.
With the completion of the acquisition, a number of Kairos staff will join Zymeworks, including John Babcook, president and chief scientific officer of Kairos, who will join Zymeworks as senior vice president of Discovery Research.
Along with key scientific talent, the Kairos acquisition provides Zymeworks with a proprietary next-generation antibody-drug conjugate platform based on novel toxin, linker, and site-specific conjugation technology.
This platform is synergistic with Zymeworks' Azymetric, AlbuCORE, and EFECT technologies and will enable the design of highly targeted and potent bi-specific antibodies and multivalent protein therapeutics across a range of indications.
The Kairos platform has the potential to be a key enabler of personalized medicine as it allows for the development of therapeutics that target cancer with increased potency and efficacy, while reducing toxic side-effects.
Zymeworks is transitioning to a clinical stage company, with its two lead compounds nearing first-in-human clinical trials. In addition to its platform technology, Kairos brings a pipeline of partnered ADCs targeting novel cancer targets with the potential to move into clinical development in the near term.
The combined company will continue to be headquartered in Vancouver. Financial details were not disclosed.
Zymeworks is a privately held biotherapeutics company that is developing Azymetric bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases.
The company's novel Azymetric, AlbuCORE, and EFECT platforms, its Zymelink conjugation platform and cytotoxins, and its proprietary ZymeCAD structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies, multivalent protein therapeutics, and antibody drug conjugates across a range of indications.
Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programmes and strategic collaborations.
Target: Kairos Therapeutics
Buyer: Zymeworks Inc
Deal size in USD:
Type: Corporate Acquisition
Buyer advisor: , ,
Comment: Terms of the deal were not disclosed
|Printer friendly Cite/link Email Feedback|
|Publication:||M & A Navigator|
|Date:||Mar 23, 2016|
|Previous Article:||CNG's Lindenmeyr Munroe Division Acquires Minnesota's C.J. Duffey Paper.|
|Next Article:||Healthcare Collaboration Specialists Practice Unite, Uniphy Health Merge Operations.|